100 Innovation Drive
Suite 290
Winnipeg, MB R3T 6G2
Canada
204-453-1301
https://kanebiotech.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Marc Edwards | President, CEO & Director | 268.5k | N/A | N/A |
Mr. Ray Dupuis | Chief Financial Officer | 161.69k | N/A | N/A |
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC | Executive Chairman & Member of Scientific Advisory Board | N/A | N/A | 1965 |
Dr. Gregory S. Schultz Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | N/A | N/A | 1950 |
Lorne Gorber | Investor Relations | N/A | N/A | N/A |
Nicole Sendey | Investor Relations Adviser | N/A | N/A | N/A |
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Kane Biotech Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.